Fox Foundation's Parkinson's initiative expands into Australia; Qiagen, Pfizer partner on molecular diagnostic test;

> The Michael J. Fox Foundation's Parkinson's Progression Markers Initiative has expanded into Australia, where the foundation is currently recruting people to join the global study. Story

> A group of proteins called the Bcl-2 family could be markers to predict which patients will most benefit from a new drug to treat chronic leukemia. Story

> Germany's Qiagen is partnering with Pfizer to develop a companion molecular diagnostic test that would be used with an investigative Pfizer drug for non-small cell lung cancer. Financial terms were not disclosed. Release

> Quanterix, a Cambridge, MA-based company developing ultra-sensitive detection systems for use in research and in-vitro diagnostics, says its high sensitivity digital ELISA helped a pilot study identify inflammation biomarkers from patients with Crohn's disease. Quanterix release

> Biomarker patent application of the week: Novel groups of biomarkers for diagnosing Alzheimer's disease. Patent application

Suggested Articles

AI-based drug molecule designer XtalPi has secured a mammoth funding round totaling $318.8 million, from global banking and tech investors.

LabCorp has licensed a blood test from Genfit designed to identify patients with risky cases of the liver disease NASH.

Philips has launched a compact, single-use device for physically clearing potentially dangerous blood clots lodged in the arms and legs.